Blue Cross Blue Shield of Mississippi
site map

About Us   Careers    Site Map

  • Be Healthy
  • I'm a Member
  • I'm a Provider
  • I'm an Employer
  • Find Coverage

I'm a provider

You will be redirected to myBlue. Would you like to continue?

please waitPlease wait while you are redirected.

myBlue login
 Username:
 Password:
  • Forgot Password »
  • More Information »

be RxSmart

Medical & Coding Policies

Provider Network Application

Out-of-State & Non-Network

Contact Us

Provider Links

Healthy You! Provider Information »

E-solutions & Online Tools »

Provider Forms »

Articles & Updates »

National Provider Identifier »

Good Health Club for Kids »

Medical Policy Search
Printer Friendly Version Functional Magnetic Resonance Imaging (MRI)

Functional Magnetic Resonance Imaging (MRI)

 

DESCRIPTION

Functional magnetic resonance imaging (fMRI) is a noninvasive method for evaluation of eloquent brain areas.  Images are collected while specific activities are performed in order to assist in the presurrgical localization of critical cortical areas and evaluation of language lateralization.

Before neurological surgery for seizure disorders or resection of brain tumors, localization of certain areas of the brain, such as speech centers, is important. For example, from 25% to 60% of patients who undergo left anterior temporal lobectomy develop dysnomia (language/naming difficulties). Most often these “eloquent” areas are assessed using the Wada test and direct electrical simulation. Both of these tests are invasive and both also require involvement of various specialists. The Wada test involves angiography and injection of amobarbital into the carotid artery. Direct electrical stimulation involves surgical placement of electrodes in the brain. Functional Magnetic Resonance Imaging (MRI) is proposed as a noninvasive alternative method for evaluation of these eloquent brain areas. Functional MR imaging uses sequences based on T2-weighted blood oxygen. Images are collected as various activities are conducted. Laterality indices are calculated reflecting the interhemispheric difference between activated volumes in the left and right hemispheric regions of interest. These studies are often done on MR scanners with field strengths of 1.5 Tesla or greater. 

Functional MRI is an activation method that uses sequences based on T2-weighted blood oxygen (BOLD). These studies are often done on MR scanners with field strengths of 1.5 Tesla or greater. The interhemispheric difference between activated volumes in the left and right hemispheric regions of interest is calculated as the laterality index, which ranges from -1 to 1. A positive laterality index is considered left-dominant, while a negative laterality index is right dominant. Functional MRI-determined laterality indices may be derived for several different functional areas (regions of interest) that include either Broca’s area (language production) or Wernicke’s area (language comprehension). Various thresholds (e.g., -0.1 to +0.1, or -0.5 to +0.5) have been proposed to differentiate laterality from bilaterality. Bilateral activation patterns can result from the detection of language-associated, but not language-essential cortex. Therefore, bilateral activation is not necessarily indicative of a bilateral distribution of language-essential cortex and may be task dependent. In addition, sensitivity and specificity may change with the application of different statistical thresholds.

 

POLICY

Functional MRI is considered medically necessary as a complementary test in the preoperative evaluation of patients with refractory epilepsy or brain tumors who are candidates for neurosurgery when the lesion is in close proximity to an eloquent area of the brain (e.g., controlling verbal or motor fuction) and testing is expected to have an important role in assessing the spatial relationship between the lesion and eloquent brain area.

Functional MRI is considered investigational for all other applications.

 

POLICY EXCEPTIONS

Federal Employee Program (FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.

 

POLICY GUIDELINES

Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary.

The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.

 

POLICY HISTORY

12/21/2006: Policy added

3/22/2007: Reviewed and approved by the Medical Policy Advisory Committee (MPAC)

6/19/2009: Policy reviewed, policy statement re-written for clarity

07/09/2010:  Policy description updated regarding use of functional MRI. Added "as a complementary test" to the policy statement; intent unchanged. FEP verbiage added to the Policy Exceptions section.

08/02/2011: Policy reviewed; no changes.

07/17/2012: Policy reviewed; no changes.

 

SOURCE(S)

Blue Cross Blue Shield Association Policy # 6.01.47

 

CODE REFERENCE

This is not intended to be a comprehensive list of codes. Some covered procedure codes have multiple descriptions.

The code(s) listed below are ONLY covered if the procedure is performed according to the "Policy" section of this document.   

Covered Codes

Code Number

Description

CPT-4

70554

Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration (new 1-1-2007)

70555

Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing (new 1-1-2007)

96020

Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping, with test administered entirely by a physician or psychologist, with review of test results and report (new 1-1-2007)

ICD-9 Procedure

 

 

ICD-9 Diagnosis

191.0, 191.1, 191.2, 191.3, 191.4, 191.5, 191.6, 191.7, 191.8, 191.9Malignant Neoplasm of Brain

198.3

Secondary malignant neoplasm of other specified sites

225.0

Benign neoplasm of brain

237.5

Neoplasm of uncertain behavior of brain and spinal cord

239.6

Neoplasm of unspecified nature of brain

345.00, 345.01, 345.10, 345.11, 345.2, 345.3, 345.40, 345.41, 345.50, 345.51Epilepsy

780.39

Other convulsions

HCPCS

 

 

 

Top




Copyright © 2007-2013, Blue Cross & Blue Shield of Mississippi, A Mutual Insurance Company. All Rights Reserved.
An independent licensee of the Blue Cross and Blue Shield Association.

About Us  ·   Careers   ·   Terms of Use  ·   Privacy Practices  ·   Accreditation  ·   Site Map